GILEAD SCIENCES, INC. (GILD)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 7,082 | 6,667 | 7,545 | 6,954 |
| Selling, general and administrative expenses | 1,365 | 1,258 | 1,433 | 1,377 |
| Research and development expenses | 1,491 | 1,379 | 1,395 | 1,351 |
| Acquired in-process research and development expenses | 61 | 253 | 505 | 38 |
| In-process research and development impairments | 190 | - | 1,750 | - |
| Cost of goods sold | 1,501 | 1,540 | 1,574 | 1,544 |
| Total costs and expenses | 4,608 | 4,430 | 6,657 | 4,309 |
| Operating income (loss) | 2,474 | 2,237 | 888 | 2,644 |
| Other (income) expense, net | 208 | -328 | 306 | -355 |
| Interest expense | 254 | 260 | 238 | 237 |
| Income (loss) before income taxes | 2,429 | 1,649 | 956 | 2,053 |
| Income tax expense | 468 | 334 | -297 | 438 |
| Net income (loss) | 1,960 | 1,315 | 1,253 | 1,614 |
| Net income attributable to noncontrolling interest | - | - | - | - |
| Net income (loss) attributable to gilead | 1,960 | 1,315 | 1,253 | 1,614 |
| Basic earnings (loss) per share attributable to gilead (in dollars per share) | 1.57 | 1.06 | 1 | 1.29 |
| Diluted earnings (loss) per share attributable to gilead (in dollars per share) | 1.56 | 1.04 | 1 | 1.29 |
| Shares used in basic earnings (loss) per share attributable to gilead calculation (in shares) | 1,245,000,000 | 1,246,000,000 | 1,247,000,000 | 1,247,000,000 |
| Shares used in diluted earnings (loss) per share attributable to gilead calculation (in shares) | 1,255,000,000 | 1,259,000,000 | 1,254,000,000 | 1,251,000,000 |